{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:35:50Z","timestamp":1793352950978,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtha.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:47:29Z","timestamp":1786492049000},"page":"3981-3988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the effects of abelacimab, asundexian, and milvexian on medical device-induced clotting and thrombin generation in vitro"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0918-5537","authenticated-orcid":false,"given":"Xinyi","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1223-0754","authenticated-orcid":false,"given":"James C.","family":"Fredenburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-7550","authenticated-orcid":false,"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.08.002_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(09)60220-8","article-title":"Management of occlusion and thrombosis associated with long-term indwelling central venous catheters","volume":"374","author":"Baskin","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.08.002_bib2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.CIR.89.2.635","article-title":"Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses","volume":"89","author":"Cannegieter","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.08.002_bib3","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.002_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2026.08.002_bib5","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2023020719","article-title":"Biology of factor XI","volume":"143","author":"Moellmer","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.002_bib6","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.jtha.2025.06.028","article-title":"Effects of milvexian alone or with heparin on catheter-induced clotting and thrombin generation","volume":"23","author":"Yin","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.002_bib7","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.002_bib8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.002_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40119-024-00379-0","article-title":"Milvexian: an oral, bioavailable factor XIa inhibitor","volume":"13","author":"Parsa","year":"2024","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.jtha.2026.08.002_bib10","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.002_bib11","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.jtha.2026.08.002_bib12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"Capodanno","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jtha.2026.08.002_bib13","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1182\/blood-2011-07-364141","article-title":"Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo","volume":"118","author":"Yau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.002_bib14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtha.2026.08.002_bib15","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2026.08.002_bib16","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.jtha.2026.02.020","article-title":"Rationale for the milvexian dosing in the phase 3 LIBREXIA program","volume":"24","author":"Weitz","year":"2026","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.002_bib17","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1016\/j.jtha.2025.06.016","article-title":"Effect of heparins, direct oral anticoagulants, and factor XII\/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study","volume":"23","author":"Hardy","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.002_bib18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran vs. warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.002_bib19","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.athoracsur.2019.10.091","article-title":"Rivaroxaban and dabigatran for suppression of mechanical heart valve\u2013induced thrombin generation","volume":"110","author":"Jaffer","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtha.2026.08.002_bib20","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jtha.2026.08.002_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jtcvs.2024.07.011","article-title":"There is still no alternative to warfarin for mechanical valves: it remains the most effective anticoagulant","volume":"170","author":"Mack","year":"2025","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtha.2026.08.002_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.002_bib23","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.002_bib24","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","article-title":"Design and preclinical characterization program toward asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders","volume":"66","author":"Roehrig","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.jtha.2026.08.002_bib25","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:02:14Z","timestamp":1793350934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626005192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1538783626005192"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.002","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the effects of abelacimab, asundexian, and milvexian on medical device-induced clotting and thrombin generation in vitro","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}